Phase II Study of the Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab for Hormone Therapy Refractory Patients With Her-2/Neu 1+ or 2+ Expressing Advanced or Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 12 May 2015
At a glance
- Drugs Ertumaxomab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Neovii Biotech
- 10 Jun 2017 Biomarkers information updated
- 20 May 2009 Planned end date (1 Feb 2009) added as reported by Clinicaltrials.gov..
- 20 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.